Skip to main content
Top
Published in: Digestive Diseases and Sciences 12/2006

01-12-2006 | Original Paper

Increased Activity and Expression of Gelatinases in Ischemic Colitis

Authors: Carlos Medina, Alfredo Santana, Maria Cristina Paz-Cabrera, Adolfo Parra-Blanco, David Nicolás, Antonio Z. Gimeno-Garcia, Enrique Quintero

Published in: Digestive Diseases and Sciences | Issue 12/2006

Login to get access

Abstract

Ischemic colitis results from insufficient blood supply but its pathogenesis is poorly understood. The aim of this study was to determine whether the activity and expression of gelatinases (MMP-9 and MMP-2) are increased in the colonic mucosa of patients with ischemic colitis. MMP-9 and MMP-2 activity and expression were assessed in colonic mucosal specimens from 8 patients with acute ischemic colitis and in 12 controls with a normal colonoscopy. The activity and expression of MMP-9 and MMP-2 were quantified in tissue samples by zymography and western blot, respectively. Colonoscopy was repeated 12 weeks after discharge in two patients and MMP activity was assessed in the slight residual mucosal changes of ischemic colitis. In patients with ischemic colitis, a significant increase in total MMP-9 and MMP-2 activity and expression was found in ulcerated areas compared with noninvolved sites of mucosa. Following resolution of ischemic ulcers the proteolytic activity returned to baseline levels. In addition, the colonic mucosa of controls showed MMP-2 activity, whereas the MMP-9 activity was negligible or not detected. We conclude that ischemic colitis induces increased activity and expression of MMP-9 and MMP-2 in the involved colonic mucosa. These changes may contribute to tissue degradation and remodeling of the colonic mucosa in ischemic colitis.
Literature
1.
go back to reference Bower TC (1993) Ischemic colitis. Surg Clin North Am 73:1037–1053PubMed Bower TC (1993) Ischemic colitis. Surg Clin North Am 73:1037–1053PubMed
2.
go back to reference Gandhi SK, Hanson MM, Vernava AM, Kamiski DL, Longo WE (1996) Ischemic colitis. Dis Colon Rectum 39:88–100CrossRefPubMed Gandhi SK, Hanson MM, Vernava AM, Kamiski DL, Longo WE (1996) Ischemic colitis. Dis Colon Rectum 39:88–100CrossRefPubMed
4.
go back to reference Medina C, Vilaseca J, Videla S, Fabra R, Armengol-Miro JR, Malagelada JR (2004) Outcome of patients with ischemic colitis: Review of fifty-three cases. Dis Col Rectum 47:180–184CrossRef Medina C, Vilaseca J, Videla S, Fabra R, Armengol-Miro JR, Malagelada JR (2004) Outcome of patients with ischemic colitis: Review of fifty-three cases. Dis Col Rectum 47:180–184CrossRef
5.
go back to reference Barouk J, Gournay J, Bernard P, Masliah C, Le Neel JC, Galmiche JP (1999) Ischemic colitis in the elderly: predictive factors of gangrenous outcome. Gastroenterol Clin Biol 23:470–474PubMed Barouk J, Gournay J, Bernard P, Masliah C, Le Neel JC, Galmiche JP (1999) Ischemic colitis in the elderly: predictive factors of gangrenous outcome. Gastroenterol Clin Biol 23:470–474PubMed
6.
go back to reference Woessner FJR (1991) Matrix metalloproteinases and their inhibitors in connective tissue remodeling. FASEB J 5:2145–2154PubMed Woessner FJR (1991) Matrix metalloproteinases and their inhibitors in connective tissue remodeling. FASEB J 5:2145–2154PubMed
7.
go back to reference Woessner FJR (1991) Literature on vertebrate matrix metalloproteinases and their tissue inhibitors. Matrix 1:425–501 Woessner FJR (1991) Literature on vertebrate matrix metalloproteinases and their tissue inhibitors. Matrix 1:425–501
9.
go back to reference Nagase H, Barrett AJ, Woessner JR (1992) Nomenclature and glossary of the matirx metalloproteinases. Matrix 1:421–424PubMed Nagase H, Barrett AJ, Woessner JR (1992) Nomenclature and glossary of the matirx metalloproteinases. Matrix 1:421–424PubMed
10.
11.
go back to reference Borkakoti N (1998) Matrix metalloproteinases: variations on a theme. Prog Biophys Mol Biol 70:73–94CrossRefPubMed Borkakoti N (1998) Matrix metalloproteinases: variations on a theme. Prog Biophys Mol Biol 70:73–94CrossRefPubMed
12.
go back to reference Nelson AR, Fingleton B, Rothenberg ML, Matrisian LM (2000) Matrix metalloproteinases: Biologic activity and clinical implications. J Clin Oncol 18:1135–1149PubMed Nelson AR, Fingleton B, Rothenberg ML, Matrisian LM (2000) Matrix metalloproteinases: Biologic activity and clinical implications. J Clin Oncol 18:1135–1149PubMed
13.
go back to reference Meikle MC, Atkinson SJ, Ward RV, Murphy G, Reynolds JJ (1989) Gingival fibroblasts degrade type I collagen films when stimulated with tumor necrosis factor and interleukin 1: evidence that breakdown is mediated by metalloproteinases. J Periodontal Res 24:207–213CrossRefPubMed Meikle MC, Atkinson SJ, Ward RV, Murphy G, Reynolds JJ (1989) Gingival fibroblasts degrade type I collagen films when stimulated with tumor necrosis factor and interleukin 1: evidence that breakdown is mediated by metalloproteinases. J Periodontal Res 24:207–213CrossRefPubMed
14.
go back to reference Konttinen YT, Ceponis A, Takagi M, Ainola M, Sorsa T, Sutinen M, Salo T, Ma J, Santavirta S, Seiki M (1998) New collagenolytic enzymes/cascade identified at the pannus–hard tissue junction in rheumatoid arthritis: destruction from above. Matrix Biol 17:585–601CrossRefPubMed Konttinen YT, Ceponis A, Takagi M, Ainola M, Sorsa T, Sutinen M, Salo T, Ma J, Santavirta S, Seiki M (1998) New collagenolytic enzymes/cascade identified at the pannus–hard tissue junction in rheumatoid arthritis: destruction from above. Matrix Biol 17:585–601CrossRefPubMed
15.
go back to reference Rajagopalan S, Meng XP, Ramasamy S, Harrison DG, Galis ZS (1996) Reactive oxygen species produced by macrophage-derived foams cells regulate the activity of vascular matrix metalloproteinases in vitro: Implications for atherosclerotic plaque stability. J Clin Invest 98:2572–2579PubMed Rajagopalan S, Meng XP, Ramasamy S, Harrison DG, Galis ZS (1996) Reactive oxygen species produced by macrophage-derived foams cells regulate the activity of vascular matrix metalloproteinases in vitro: Implications for atherosclerotic plaque stability. J Clin Invest 98:2572–2579PubMed
16.
go back to reference Baugh M, Perry M, Hollander A, Davies DR, Cross SS, Lobo AJ, Taylor CJ, Evans GS (1999) Matrix metalloproteinases levels are elevated in inflammatory bowel disease. Gastroenterology 117:814–822CrossRefPubMed Baugh M, Perry M, Hollander A, Davies DR, Cross SS, Lobo AJ, Taylor CJ, Evans GS (1999) Matrix metalloproteinases levels are elevated in inflammatory bowel disease. Gastroenterology 117:814–822CrossRefPubMed
17.
go back to reference Von Lampe B, Barthel B, Coupland SE, Riecken EO, Rosewicz S (2000) Differential expression of matrix metalloproteinases and their tissue inhibitors in colon mucosa of patients with inflammatory bowel disease. Gut 47:63–73CrossRefPubMed Von Lampe B, Barthel B, Coupland SE, Riecken EO, Rosewicz S (2000) Differential expression of matrix metalloproteinases and their tissue inhibitors in colon mucosa of patients with inflammatory bowel disease. Gut 47:63–73CrossRefPubMed
18.
go back to reference Heuschkel RB, MacDonald TT, Monteleone G, Bajaj-Elliott M, Smith JA, Pender SL (2000) Imbalance of stromelysin 1 and TIMP 1 in the mucosal lesions of children with inflammatory bowel disease. Gut 47:57–62CrossRefPubMed Heuschkel RB, MacDonald TT, Monteleone G, Bajaj-Elliott M, Smith JA, Pender SL (2000) Imbalance of stromelysin 1 and TIMP 1 in the mucosal lesions of children with inflammatory bowel disease. Gut 47:57–62CrossRefPubMed
19.
go back to reference Stallmach A, Chan CC, Ecker KW, Feifel G, Herbst H, Schuppan D, Zeitz M (2000) Comparable expression of matrix metalloproteinases 1 and 2 in pouchitis and ulcerative colitis. Gut 47:415– 422CrossRefPubMed Stallmach A, Chan CC, Ecker KW, Feifel G, Herbst H, Schuppan D, Zeitz M (2000) Comparable expression of matrix metalloproteinases 1 and 2 in pouchitis and ulcerative colitis. Gut 47:415– 422CrossRefPubMed
20.
go back to reference Daum S, Bauer U, Foss HD, Wahnschaffe U, Schuppan D, Stein H, Riecken EO, Ullrich R (1999) Increased expression of mRNA for matrix metalloproteinases-1 and -3 and tissue inhibitor of metalloproteinases-1 in intestinal biopsy specimens from patients with coeliac disease. Gut 44:17–25PubMedCrossRef Daum S, Bauer U, Foss HD, Wahnschaffe U, Schuppan D, Stein H, Riecken EO, Ullrich R (1999) Increased expression of mRNA for matrix metalloproteinases-1 and -3 and tissue inhibitor of metalloproteinases-1 in intestinal biopsy specimens from patients with coeliac disease. Gut 44:17–25PubMedCrossRef
21.
go back to reference Pender S, Tickle S, Docherty A, Howie D, Wathen NC, MacDonald TT (1997) A major role for matrix metalloproteinases in T cell injury in the gut. J Immunol 158:1582–1590PubMed Pender S, Tickle S, Docherty A, Howie D, Wathen NC, MacDonald TT (1997) A major role for matrix metalloproteinases in T cell injury in the gut. J Immunol 158:1582–1590PubMed
22.
go back to reference Pender SL, Fell JM, Chamow SM, Ashkenazi A, MacDonald TT (1998) A p55 TNF receptor immunoadhesin prevents T cell-mediated intestinal injury by inhibiting matrix metalloproteinases production. J Immunol 160:4098–4103PubMed Pender SL, Fell JM, Chamow SM, Ashkenazi A, MacDonald TT (1998) A p55 TNF receptor immunoadhesin prevents T cell-mediated intestinal injury by inhibiting matrix metalloproteinases production. J Immunol 160:4098–4103PubMed
23.
go back to reference Pender SL, Breese EJ, Gunther U, Howie D, Wathen NC, Schuppan D, MacDonald TT (1998) Supppression of T-cell mediated injury in human gut by interleukin 10: role of matrix metalloproteinases. Gastroenterology 115:573–583CrossRefPubMed Pender SL, Breese EJ, Gunther U, Howie D, Wathen NC, Schuppan D, MacDonald TT (1998) Supppression of T-cell mediated injury in human gut by interleukin 10: role of matrix metalloproteinases. Gastroenterology 115:573–583CrossRefPubMed
24.
go back to reference Heussen C, Dowle EB (1980) Electrophoretic analysis of plasminogen activators in polyacrylamide gels containing sodium dodecylsulfate and copolymerized substrate. Anal Biochem 102:196– 202CrossRefPubMed Heussen C, Dowle EB (1980) Electrophoretic analysis of plasminogen activators in polyacrylamide gels containing sodium dodecylsulfate and copolymerized substrate. Anal Biochem 102:196– 202CrossRefPubMed
25.
go back to reference Sawicki G, Salas E, Murat J, Miszta-Lane H, Radomski MW (1997) Release of gelatinase B during platelet activation mediates aggregation. Nature 386:616–619CrossRefPubMed Sawicki G, Salas E, Murat J, Miszta-Lane H, Radomski MW (1997) Release of gelatinase B during platelet activation mediates aggregation. Nature 386:616–619CrossRefPubMed
26.
go back to reference Medina C, Videla S, Radomski A, Radomski MW, Antolín M, Guarner F, Vilaseca J, Salas A, Malagelada JR (2003) Increased activity and expression of matrix metalloproteinase-9 in a rat model of distal colitis. Am J Physiol Gastrointest Liver Physiol 284:116–122 Medina C, Videla S, Radomski A, Radomski MW, Antolín M, Guarner F, Vilaseca J, Salas A, Malagelada JR (2003) Increased activity and expression of matrix metalloproteinase-9 in a rat model of distal colitis. Am J Physiol Gastrointest Liver Physiol 284:116–122
27.
go back to reference Vaalamo M, Karjalainen-Lindsberg ML, Puolakkainen P, Kere J, Saarialho-Kere U (1998) Distinct expression profiles of stromelysin-2 (MMP-10), collagenase-3 (MMP-13), macrophage metalloelastase (MMP-12), and tissue inhibitor of metalloproteinases-3 (TIMP-3) in intestinal ulcerations. Am J Pathol 152:1005–1014PubMed Vaalamo M, Karjalainen-Lindsberg ML, Puolakkainen P, Kere J, Saarialho-Kere U (1998) Distinct expression profiles of stromelysin-2 (MMP-10), collagenase-3 (MMP-13), macrophage metalloelastase (MMP-12), and tissue inhibitor of metalloproteinases-3 (TIMP-3) in intestinal ulcerations. Am J Pathol 152:1005–1014PubMed
28.
go back to reference Salmela MT, Pender SLF, Karjalainen-Lindsberg ML, Puolakkaimen P, MacDonald TT, Saarialha-Kere U (2004) Collagenase-1 (MMP-1), matrylisin-1 (MMP7), and stromelysin-2 (MMP-10) are expressed by migrating enterocytes during intestinal wound healing. Scand J Gastroenterol 39:1095–1104CrossRefPubMed Salmela MT, Pender SLF, Karjalainen-Lindsberg ML, Puolakkaimen P, MacDonald TT, Saarialha-Kere U (2004) Collagenase-1 (MMP-1), matrylisin-1 (MMP7), and stromelysin-2 (MMP-10) are expressed by migrating enterocytes during intestinal wound healing. Scand J Gastroenterol 39:1095–1104CrossRefPubMed
29.
go back to reference Hovdenak N, Wang J, Sung CC, Nelly T, Fajardo LF, Haurer-Jensen M (2002) Clinical significance of increased gelatinolytic activity in the rectal mucosa during external beam radiation therapy of prostate cancer. Int J Radiat Oncol Biol Phys 53:919–927CrossRefPubMed Hovdenak N, Wang J, Sung CC, Nelly T, Fajardo LF, Haurer-Jensen M (2002) Clinical significance of increased gelatinolytic activity in the rectal mucosa during external beam radiation therapy of prostate cancer. Int J Radiat Oncol Biol Phys 53:919–927CrossRefPubMed
30.
go back to reference Medina C, Videla S, Radomski A, Radomski MW, Antolín M, Guarner F, Vilaseca J, Salas A, Malagelada JR (2001) Therpaeutic effect of pheantroline in two rat models of inflammatory bowel disease. Scand J Gastroenterol 36:1314–1319CrossRefPubMed Medina C, Videla S, Radomski A, Radomski MW, Antolín M, Guarner F, Vilaseca J, Salas A, Malagelada JR (2001) Therpaeutic effect of pheantroline in two rat models of inflammatory bowel disease. Scand J Gastroenterol 36:1314–1319CrossRefPubMed
31.
go back to reference Ducharme A, Frantz S, Aikawa M, Rabkin E, Lindsey M, Rohde LE, Schoen FJ, Kelly RA, Werb Z, Libby P, Lee RT (2000) Targeted deletion of matrix metalloproteinase-9 attenuates left ventricular enlargement and collagen accumulation after experimental myocardial infarction. J Clin Invest 106:55–62PubMedCrossRef Ducharme A, Frantz S, Aikawa M, Rabkin E, Lindsey M, Rohde LE, Schoen FJ, Kelly RA, Werb Z, Libby P, Lee RT (2000) Targeted deletion of matrix metalloproteinase-9 attenuates left ventricular enlargement and collagen accumulation after experimental myocardial infarction. J Clin Invest 106:55–62PubMedCrossRef
32.
go back to reference Huhtala P, Chow LT, Tryggvason K (1990) Structure of the human type IV collagenase gene. J Biol Chem 265:11077–11082PubMed Huhtala P, Chow LT, Tryggvason K (1990) Structure of the human type IV collagenase gene. J Biol Chem 265:11077–11082PubMed
33.
go back to reference Huhtala P, Eddy RL, Fan YS, Byers MG, Shows TB, Tryggvason K (1990) Completion of the primary structure of the human type IV collagenase preproenzyme and assignment of the gene (CLG4) to the q21 region of chromosome 16. Genomics 6:554–559CrossRefPubMed Huhtala P, Eddy RL, Fan YS, Byers MG, Shows TB, Tryggvason K (1990) Completion of the primary structure of the human type IV collagenase preproenzyme and assignment of the gene (CLG4) to the q21 region of chromosome 16. Genomics 6:554–559CrossRefPubMed
34.
go back to reference Cowland JB, Borregaard N (1999) The individual regulation of granule protein mRNA levels during neutrophil maturation explains the heterogeneity of neutrophil granules. J Leukok Biol 66:989–995 Cowland JB, Borregaard N (1999) The individual regulation of granule protein mRNA levels during neutrophil maturation explains the heterogeneity of neutrophil granules. J Leukok Biol 66:989–995
Metadata
Title
Increased Activity and Expression of Gelatinases in Ischemic Colitis
Authors
Carlos Medina
Alfredo Santana
Maria Cristina Paz-Cabrera
Adolfo Parra-Blanco
David Nicolás
Antonio Z. Gimeno-Garcia
Enrique Quintero
Publication date
01-12-2006
Published in
Digestive Diseases and Sciences / Issue 12/2006
Print ISSN: 0163-2116
Electronic ISSN: 1573-2568
DOI
https://doi.org/10.1007/s10620-006-9255-5

Other articles of this Issue 12/2006

Digestive Diseases and Sciences 12/2006 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine